Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of lenalidomide alone or with azacitidine or romidepsin in relapsed/refractory acute myeloid leukemia
ACTRN12612000312842Phase 2Withdrawn
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Lenalidomide alone, Azacitidine + lenalidomide and Romidepsin + lenalidomide (3 arms). Primary endpoint: Complete remission rate after two cycles. Planned start Jun 2018; status: withdrawn.
02
Drugs
lenalidomideazacitidineromidepsin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12612000312842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000312842.